Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco

References

• Varghese T, Kang G, Steele AD. Understanding rotavirus vaccine efficacy and effectiveness in countries with high child mortality. Nato Adv Sci Inst Se. 2022;10(3):346. doi:10.3390/vaccines10030346.
   Google Scholar
• Kraay ANM, Chaney DM, Deshpande A, Pitzer VE, Lopman BA. Predicting indirect effects of rotavirus vaccination programs on rotavirus mortality among children in 112 countries. NPJ Vaccines. 2023;8(1):32. doi:10.1038/s41541-023-00632-y.
   PubMed Web of Science ®Google Scholar
• Vetter V, Gardner RC, Debrus S, Benninghoff B, Pereira P. Established and new rotavirus vaccines: a comprehensive review for healthcare professionals. Hum Vaccin Immunother. 2022;18(1):1870395. doi:10.1080/21645515.2020.1870395.
   PubMed Web of Science ®Google Scholar
• Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagbom M, Franco MA, Greenberg HB, O’Ryan M, Kang G. et al. Rotavirus infection. Nat Rev Dis Primers. 2017;3(1):17083. doi:10.1038/nrdp.2017.83.
   PubMed Web of Science ®Google Scholar
• Burke RM, Tate JE, Parashar UD. Global experience with rotavirus vaccines. J Infect Dis. 2021;224(12 Suppl 2):792–13. doi:10.1093/infdis/jiab399.
   Google Scholar
• Benhafid M, Elomari N, Azzouzi Idrissi M, Rguig A, Gentsch JR, Parashar U, Elaouad R. Effect of monovalent rotavirus vaccine on rotavirus disease burden and circulating rotavirus strains among children in Morocco. J Med Virol. 2015;87(6):944–53. doi:10.1002/jmv.24122.
   PubMed Web of Science ®Google Scholar
• Ezzine H, Rguig A, N M, Jroundi I. Trends for rotavirus acute gastroenteritis in children under 5 years old before and after vaccine introduction, Morocco, 2006–2014. East Mediterr Health J. 2021;27(6):553–62. doi:10.26719/2021.27.6.553.
   Web of Science ®Google Scholar
• Debellut F, Clark A, Pecenka C, Tate J, Baral R, Sanderson C, Parashar U, Atherly D. Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for gavi funding: a modelling study. Lancet Glob Health. 2021;9(7):942–56. doi:10.1016/S2214-109X(21)00167-4.
   Web of Science ®Google Scholar
• Haut-Commissariat Au Plan. Indicateurs Structure de la population 2023. Available from: https://www.hcp.ma/Projections-de-la-population-totale-du-Maroc-par-age-simple-et-sexe-2014-2050_a2209.html.
   Google Scholar
• Bakir M, Standaert B, Turel O, Bilge ZE, Postma M. Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. Vaccine. 2013;31(6):979–86. doi:10.1016/j.vaccine.2012.11.071.
   PubMed Web of Science ®Google Scholar
• Alkoshi S, Maimaiti N, Dahlui M. Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model. Libyan J Med. 2014;9(1):26236. doi:10.3402/ljm.v9.26236.
   PubMedGoogle Scholar
• Saokaew S, Prasitsuebsai W, Bibera GL, Kengkla K, Zhang X-H, Oh K-B, Lee C. Economic evaluation of human rotavirus vaccine in Thailand. Infect Dis Ther. 2019;8(3):397–415. doi:10.1007/s40121-019-0246-1.
   PubMed Web of Science ®Google Scholar
• Mohy A, Page N, Boyce W, Gomez JA. Economic evaluation of rotavirus vaccination in children aged under five years in South Africa. Clin Drug Investig. 2023;43(11):851–63. doi:10.1007/s40261-023-01312-4.
   PubMed Web of Science ®Google Scholar
• Gomez J, Castillo FRV, Guzman-Holst A, Cervantes Apolinar MY, Van Bellinghen L-A, Van Vlaenderen I, van Oorschot D. Cost-effectiveness analysis measuring the total costs against the health benefits of three different rotavirus vaccines for Mexico. Hum Vaccin Immunother. 2023;19(2):2219189. doi:10.1080/21645515.2023.2219189.
   PubMed Web of Science ®Google Scholar
• Chen Y. Health technology assessment and economic evaluation: is it applicable for the traditional medicine? Integr Med Res. 2022;11(1):100756. doi:10.1016/j.imr.2021.100756.
   PubMed Web of Science ®Google Scholar
• Standaert B, Sauboin C, DeAntonio R, Marijam A, Gomez J, Varghese L, Zhang S. How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future. J Mark Access Health Policy. 2020;8(1):1719588. doi:10.1080/20016689.2020.1719588.
   PubMedGoogle Scholar
• Brüggenjürgen B, Lorrot M, Sheppard FR, Rémy V. Do current cost-effectiveness analyses reflect the full value of childhood vaccination in Europe? A rotavirus case study. Hum Vaccin Immunother. 2014;10(8):2290–4. doi:10.4161/hv.29090.
   PubMed Web of Science ®Google Scholar
• Standaert B, Parez N, Tehard B, Colin X, Detournay B. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy. 2008;6(4):199–216. doi:10.1007/BF03256134.
   PubMedGoogle Scholar
• Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ. 2008;11(3):471–84. doi:10.3111/13696990802321047.
   PubMedGoogle Scholar
• Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. In: Agota Szende B, and Cabases J. editors. Dordrecht (NL): Springer; 2014. p. 146.
   Google Scholar
• World Health Organization. Healthy life expectancy (HALE) data by country 2020. accessed 2023 May https://apps.who.int/gho/data/node.main.HALE?lang=fr.
   Google Scholar
• Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. Vaccine. 2015;33(32):3788–94. doi:10.1016/j.vaccine.2015.06.084.
   PubMed Web of Science ®Google Scholar
• Organisation for Economic Co-operation and Development. Exchange rates 2022. accessed 2023 Mar 30 https://data.oecd.org/conversion/exchange-rates.htm#indicator-chart.
   Google Scholar
• Pan American Health Organization. PAHO Revolving fund vaccine prices for 2021 [18/05/2022]. Available from: https://www.paho.org/en/documents/paho-revolving-fund-vaccine-prices-2021-0.
   Google Scholar
• Loganathan T, Ng CW, Lee WS, Hutubessy RCW, Verguet S, Jit M. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. Health Policy And Plann. 2018;33(2):204–14. doi:10.1093/heapol/czx166.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccine wastage rates calculator 2021. accessed 2023 Mar 30 https://www.who.int/publications/m/item/vaccine-wastage-rates-calculator.
   Google Scholar
• The World Bank. Adjusted net national income per capital (current US$) - Morocco 2020. accessed 2023 May 05 https://data.worldbank.org/indicator/NY.ADJ.NNTY.PC.CD?locations=MA.
   Google Scholar
• The World Bank. GDP per capita (current US$) - Morocco 2021. accessed 2022 Nov 15 https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=MA.
   Google Scholar
• Benhafid M, Youbi M, Klena JD, Gentsch J, Teleb N, Widdowson M-A, ElAouad R. Epidemiology of rotavirus gastroenteritis among children <5 years of age in Morocco during 1 year of sentinel hospital surveillance, June 2006–May 2007. J Infect Dis. 2009;200(1):70–5. doi:10.1086/605048.
   Google Scholar
• Benhafid M, Rguig A, Trivedi T, Elqazoui M, Teleb N, Mouane N, Maltouf AF, Parashar U, Patel M, Aouad RE. et al. Monitoring of rotavirus vaccination in Morocco: establishing the baseline burden of rotavirus disease. Vaccine. 2012;30(46):6515–20. doi:10.1016/j.vaccine.2012.08.058.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Summary of key characteristics of WHO prequalified rotavirus vaccines 2021 [02/2024]. Available from: https://iris.who.int/bitstream/handle/10665/344642/WHO-IVB-2021.03-eng.pdf?sequence=1.
   Google Scholar
• Saraiva FO, Minamisava R, Vieira MA, Bierrenbach AL, Andrade AL. Vaccination coverage and compliance with three recommended schedules of 10-valent pneumococcal conjugate vaccine during the first year of its introduction in Brazil: a cross-sectional study. PLOS ONE. 2015;10(6):e0128656. doi:10.1371/journal.pone.0128656.
   PubMed Web of Science ®Google Scholar
• Tilson L, Jit M, Schmitz S, Walsh C, Garvey P, McKeown P, Barry M. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine. 2011;29(43):7463–73. doi:10.1016/j.vaccine.2011.07.056.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Morocco: WHO and UNICEF estimates of immunization coverage 2021 [05/2023]. Available from: https://data.unicef.org/wp-content/uploads/2022/07/mar.pdf.
   Google Scholar
• Khoury H, Ogilvie I, El Khoury AC, Duan Y, Goetghebeur MM. Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population. BMC Infect Dis. 2011;11(1):9. doi:10.1186/1471-2334-11-9.
   PubMedGoogle Scholar
• Standaert B, Rappuoli R. Towards a more comprehensive approach for a total economic assessment of vaccines? J Mark Access Health Policy. 2017;5(1):1335162. doi:10.1080/20016689.2017.1335162.
   PubMedGoogle Scholar
• Standaert B, Rappuoli R. How is the economic assessment of vaccines performed today? J Mark Access Health Policy. 2017;5(1):1335163. doi:10.1080/20016689.2017.1335163.
   PubMedGoogle Scholar
• Jonesteller CL, Burnett E, Yen C, Tate JE, Parashar UD. Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006–2016. Clin Infect Dis. 2017;65(5):840–50. doi:10.1093/cid/cix369.
   PubMed Web of Science ®Google Scholar
• Burnett E, Parashar UD, Tate JE. Real-world effectiveness of rotavirus vaccines, 2006-2013: a literature review and meta-analysis. Lancet Glob Health. 2020;8(9):1195–202. doi:10.1016/S2214-109X(20)30262-X.
   PubMed Web of Science ®Google Scholar
• Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S. Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance. Hum Vaccin Immunother. 2016;12(5):1235–43. doi:10.1080/21645515.2015.1136041.
   PubMed Web of Science ®Google Scholar
• Krishnarajah G, Davis EJ, Fan Y, Standaert BA, Buikema AR. Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States. Vaccine. 2012;30(24):3717–22. doi:10.1016/j.vaccine.2011.12.077.
   PubMed Web of Science ®Google Scholar
• Krishnarajah G, Landsman-Blumberg P, Eynullayeva E. Rotavirus vaccination compliance and completion in a Medicaid infant population. Vaccine. 2015;33(3):479–86. doi:10.1016/j.vaccine.2014.06.059.
   PubMed Web of Science ®Google Scholar
• Luna-Casas G, Juliao P, Carreño-Manjarrez R, Castañeda-Prado A, Cervantes-Apolinar MY, Navarro-Rodriguez R, Sánchez-González G, Cortés-Alcalá R, DeAntonio R. Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines. Hum Vaccin Immunother. 2019;15(6):1251–9. doi:10.1080/21645515.2018.1540827.
   PubMed Web of Science ®Google Scholar
• Debellut F, Clark A, Pecenka C, Tate J, Baral R, Sanderson C, Parashar U, Kallen L, Atherly D. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. Lancet Glob Health. 2019;7(12):1664–74. doi:10.1016/S2214-109X(19)30439-5.
   PubMed Web of Science ®Google Scholar
• Henschke N, Bergman H, Hungerford D, Cunliffe NA, Grais RF, Kang G, Parashar UD, Wang SA, Neuzil KM. The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality. Vaccine. 2022;40(12):1707–11. doi:10.1016/j.vaccine.2022.02.003.
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL. et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22. doi:10.1056/NEJMoa052434.
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Guerrero ML, Bautista-Márquez A, Ortega-Gallegos H, Tuz-Dzib F, Reyes-González L, Rosales-Pedraza G, Martínez-López J, Castañón-Acosta E, Cervantes Y. et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics. 2007;120(2):253–61. doi:10.1542/peds.2006-2630.
   PubMed Web of Science ®Google Scholar
• Perez-Schael I, Salinas B, Tomat M, Linhares A, Guerrero M, Ruiz‐Palacios G, Bouckenooghe A, Yarzábal J. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. J Infect Dis. 2007;196(4):537–40. doi:10.1086/519687.
   PubMed Web of Science ®Google Scholar
• Levin A, Burgess C. Static and dynamic modeling. In: Bishai D; Brenzel L, and Padula W. editors. Handbook of Applied Health Economics in vaccines. Oxford, United Kingdom: Oxford University Press; 2023. pp. 279–89.
   Google Scholar
• Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics. 2011;29(5):371–86. doi:10.2165/11539960-000000000-00000.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Expert opinion on rotavirus vaccination in infancy 2017 [02/2024]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/rotavirus-vaccination-expert%20opinion-september-2017.pdf.
   Google Scholar
• Bennett A, Pollock L, Bar-Zeev N, Lewnard JA, Jere KC, Lopman B, Iturriza-Gomara M, Pitzer VE, Cunliffe NA. Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study. Lancet Infect Dis. 2021 May;21(5):731–40. doi:10.1016/S1473-3099(20)30597-1.
   PubMed Web of Science ®Google Scholar
• Gunawan E, Utsumi T, Wahyuni R, Dinana Z, Sudarmo SM, Shoji I.S., Lusida MI. Post-vaccinated asymptomatic rotavirus infections: a community profile study of children in Surabaya, Indonesia. J Infect Public Health. 2019;12(5):625–9. doi:10.1016/j.jiph.2019.02.015.
   PubMed Web of Science ®Google Scholar
• Atherly D, Lewis K, Tate J, Parashar UD, Rheingans RD. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011–2030. Vaccine. 2012;30(Suppl 1):7–14. doi:10.1016/j.vaccine.2011.12.096.
   Google Scholar
• Yeung KHT, Lin SL, Clark A, McGhee SM, Janusz CB, Atherly D, Chan KC, Nelson EAS. Economic evaluation of the introduction of rotavirus vaccine in Hong Kong. Vaccine. 2021;39(1):45–58. doi:10.1016/j.vaccine.2020.10.052.
   PubMed Web of Science ®Google Scholar
• Javanbakht M, Moradi-Lakeh M, Yaghoubi M, Esteghamati A, Mansour Ghanaie R, Mahmoudi S, Shamshiri A-R, Zahraei SM, Baxter L, Shakerian S. et al. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran. Vaccine. 2015;33(1):192–200. doi:10.1016/j.vaccine.2014.12.035.
   Google Scholar
• World Health Organization. Prequalified vaccines [05/05/2023]. Available from: https://extranet.who.int/prequal/vaccines/prequalified-vaccines.
   Google Scholar